| pubmed-article:9592058 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9592058 | lifeskim:mentions | umls-concept:C0079469 | lld:lifeskim |
| pubmed-article:9592058 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:9592058 | lifeskim:mentions | umls-concept:C0299223 | lld:lifeskim |
| pubmed-article:9592058 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9592058 | pubmed:dateCreated | 1998-7-8 | lld:pubmed |
| pubmed-article:9592058 | pubmed:abstractText | Noribogaine is formed in vivo by the O-demethylation of the indole alkaloid ibogaine. We report here that noribogaine acts as a full agonist at the mu-opioid receptor. Noribogaine-stimulated guanylyl 5'gamma-[35S]thio]triphosphate ([35S]GTPgammaS) was studied in rat thalamic membranes to measure activation of guanine nucleotide binding proteins (G-proteins) in the presence of excess GDP. Noribogaine caused a 170% increase above basal [35S]GTPgammaS binding at sub-micromolar effective concentrations (EC50) in a naloxone-sensitive manner, confirming that this effect was an opioid receptor-mediated process. The level of intrinsic activity for noribogaine in these assays was comparable to the full agonists DAMGO and morphine. In contrast, ibogaine had no significant effect on [35S]GTPgammaS binding over a similar concentration range. The efficacy of noribogaine as a full mu-opioid agonist may explain ibogaine's ability to block the acute signs of opiate withdrawal and its suppressive effects on morphine self-administration. | lld:pubmed |
| pubmed-article:9592058 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9592058 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592058 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9592058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592058 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9592058 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9592058 | pubmed:issn | 0959-4965 | lld:pubmed |
| pubmed-article:9592058 | pubmed:author | pubmed-author:MashD CDC | lld:pubmed |
| pubmed-article:9592058 | pubmed:author | pubmed-author:PabloJ PJP | lld:pubmed |
| pubmed-article:9592058 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9592058 | pubmed:day | 5 | lld:pubmed |
| pubmed-article:9592058 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:9592058 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9592058 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9592058 | pubmed:pagination | 109-14 | lld:pubmed |
| pubmed-article:9592058 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:meshHeading | pubmed-meshheading:9592058-... | lld:pubmed |
| pubmed-article:9592058 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9592058 | pubmed:articleTitle | Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding. | lld:pubmed |
| pubmed-article:9592058 | pubmed:affiliation | Department of Neurology, University of Miami School of Medicine, FL 33136, USA. | lld:pubmed |
| pubmed-article:9592058 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9592058 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9592058 | lld:pubmed |
